Research

Dr. Gould and his Research Team are currently enrolling patients into the following studies:

  • STRATIFY-2, Sponsored by Biogen Idec Inc.
    Are You An MS Patient Receiving Tysabri Treatments or Considering Tysabri?
  • ORACLE, Sponsored by EMD Serono
    Are You An MS Patient With Clinically Isolated Syndrome (CIS)?

Participation in any of Dr. Gould's Clinical Trials is completely voluntary and you have the right to stop your participation at any time. Your participation in the study will have no effect on your medical care provided by us.

If you have questions regarding any of our research studies, please contact us 610.866.6614 Extension 6.

Study Details

STRATIFY-2

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: STRATIFY-2

Study Sponsor: Biogen Idec Inc.

Protocol Number: 101JC402

Are You An MS Patient Receiving Tysabri Treatments or Considering Tysabri?
You may be eligible to participate in our study.

Learn More About the STRATIFY-2 Study

What is the STRATIFY-2 Study?
The STRATIFY-2 Study will identify multiple sclerosis (MS) patients who have a specific antibody in their blood against the JC virus (JCV). Antibodies are produced by the body's immune system when it detects foreign substances. It is thought that approximately half of MS patients have antibodies to JCV. The purpose of STRATIFY-2 is to gather more information about how many MS patients being treated with TYSABRI® or who are considering beginning Tysabri have the JCV antibody in their blood and to better understand whether antibodies to JCV may be used to predict whether a patient is at higher or lower risk for developing PML

Who can participate in the STRATIFY-2 Study?
Only MS patients in the TOUCH Program and MS patients considering treatment with Tysabri can participate in this study. If you are participating in any other Tysabri clinical trial,you are not eligible to participate.

Why should I join?
If you agree to participate, you will help doctors collect information on how many MS patients have JCV antibodies and the relationship between JCV antibodies and development of PML. This information may benefit other people with MS in the future. There are no direct health benefits to you for participating in this study.

Can I change my mind?
It is always your choice to be in a study. If you sign up and later decide you do not want to continue, you may stop at any time. Simply tell your doctor. This will not affect the medical care you receive from your doctor for your MS.

What if I have questions?
If you have questions about the study or your treatment at any time during the study, ask your doctor.

Contact us 610.866.6614 Extension 6

[ back to top ]

ORACLE

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects with a First Clinical Event at High Risk of Converting to MS (ORACLE MS)

Study Sponsor: EMD Serono

Protocol Number: 28821

Are You An MS Patient With Clinically Isolated Syndrome (CIS)?
If so, you may be eligible to participate in our study.

Contact us 610.866.6614 Extension 6

[ back to top ]

Improving the Quality of
Neurologic and Sleep Health

Research Team

Jeffrey D. Gould, M.D.
Principal Investigator

Research Office:
Phone: 610.866.6614 Extension 6

ANNOUNCEMENTS:

Patient Information, EMG

Our Office Brochure

Now available: BOTOX® for Headaches

The Westfield Hospital sleep lab is now open.

Jeffrey Gould MD. has been named Chief of Medicine at Westfield Hospital, Allentown, PA.

Expanded office hours till 4:30 PM daily. Call to set up an appointment.

EMGs are also available at Westfield Hospital.

MindStreams
Get your Mind Tested

MindStreams is a standardized international computerized 1-hour test allowing us to evaluate and re-evaluate patients with certain neurological disorders.
Learn more...

Research

Are You An MS Patient Receiving Tysabri Treatments? If so, you may be eligible to participate in our research study.
Learn more...